Model: | MOS 118072-93-8 |
Place of Origin: | Zhejiang,China (Mainland) |
Brand: | MOSINTER |
Molecular Formul: | C5H10N2O7P2 |
Molecular Weight: | 272.0896 |
CAS NO.: | 118072-93-8 |
Density: | 2.13g/cm3 |
Mp: | 193-204°C (dec) |
Boiling point: | 764°C at 760 mmHg |
Flash point: | 415.8°C |
Refractive index: | 1.718 |
Vapour Pressur: | 1.53E-24mmHg at 25°C |
Zoledronic Acid (CAS: 118072-93-8)
Purity: | ≥98% |
Mp: | 193-204°C (dec) |
Boiling point: | 764°C at 760 mmHg |
Flash point: | 415.8°C |
Vapour Pressur: | 1.53E-24mmHg at 25°C |
Density: | 2.13g/cm3 |
Chemical Properties: | White crystal powder |
Molecular Formula: | C5H10N2O7P2 |
Molecular Weight | 272.0896 |
Refractive index: | 1.718 |
Zoledronic acid is a bisphosphonate antiresorptive agent and bone resorption inhibito.
Mechanism of Action
Zoledronic acid slows down bone resorption, allowing the bone-forming
cells time to rebuild normal bone and allowing bone remodeling.
Bone complications of cancer
Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma
and prostate cancer, as well as for treatingosteoporosis. It can also be used to treat hypercalcemia
of malignancy and can be helpful for treating pain from bone metastases.
It can be administered at home rather than in hospital. Such administration has shown safety and
quality-of-life benefits in breast cancer patients with bone metastases.
Osteoporosis
Zoledronic acid may be given as a 5 mg infusion once per year for treatment ofosteoporosis in
men and post-menopausal women at increased risk of fracture.
Pagets disease
As Reclast a single dose of 5 mg is used for the treatment of Paget’s disease.
Side effects
Side effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs.
Flu-like symptoms are commonly experienced after the first zoledronate infusion, although not subsequent
infusions, and are thought to occur because of its potential to activate human γδ T cells (gamma/delta T cells).
Risk of severe renal impairment. Appropriate hydration is important prior to administration & adequate calcium
and vitamin D intake prior to Aclasta therapy in patients with preexisting hypocalcaemia, and for 10 days
following Aclasta in patients with Paget’s disease of the bone. Monitor for other mineral metabolism disorders;
avoid invasive dental procedures for those who develop osteonecrosis of the jaw.
A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is
osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with
zoledronate who have had dental extractions.
Research
Zoledronic acid has been found to have a direct antitumor effect and to synergistically augment the
effects of other antitumor agents in osteosarcoma cells.
Zoledronate has shown significant benefits versus placebo over three years, with a reduced number
of vertebral fractures and improved markers of bone density. An annual dose of zoledronic acid may
also prevent recurring fractures in patients with a previous hip fracture.
Contraindications
Poor renal function (e.g. CrCl<30 mL/min)
Hypocalcemia
Pregnancy
Paralysis
You must be logged in to post a review.
Reviews
There are no reviews yet.